Hypoglycemic Events in Diabetic Patients under Non-insulin Regimens During Ramadan: A Frequentist Network Meta-Analysis
Kacimi, S. E. O.; Sukaina, M.; Elgenidy, A.; Farahat, R. A.; Cheema, H. A.; Benmelouka, A. Y.; Awad, D. M.; Belaouni, H. A.; Abdelli, M. K. E.; Tidjane, A.; Mesli, N. S.; Shah, J.; Ould Setti, M.; Afifi, A. M.; Ghozy, S.; the Ramadan Diabetes Research Group (RDRG) Collaborators,
Show abstract
BackgroundDiabetic Muslims who choose to fast during Ramadan encounter major risks such as hyperglycemia, hypoglycemia, diabetic ketoacidosis, and dehydration. Recently, newer antidiabetic agents have been found to be less likely to cause hypoglycemic emergencies. This meta-analysis aimed to present collective and conclusive results from major randomized controlled trials (RCTs) to determine the risk of hypoglycemia among patients taking oral antidiabetics during Ramadan. MethodsWe searched PubMed, Web of Science, and Google Scholar for RCTs. We performed a frequentist network meta-analysis using the "netmeta" package of R software version 4.1.1 to investigate the risk of developing hypoglycemia after taking oral antidiabetic drugs during Ramadan. ResultsNine RCTs with a total of 3464 patients were included in the final analysis. In the comparison of all antidiabetic drug classes with sulfonylureas, SGLT-2 inhibitors were associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.909), followed by GLP-1 agonists (RR, 0.31; 95% CI, 0.17-0.56; P-score, 0.799), and DDP-4 inhibitors (RR, 0.57; 95% CI, 0.43-0.75; P-score, 0.483). When comparing individual drugs, dapagliflozin was associated with the lowest hypoglycemic risk (RR, 0.18; 95% CI, 0.04-0.78; P-score, 0.874), followed by lixisenatide (RR, 0.25; 95% CI, 0.09-0.71; P-score, 0.813), liraglutide (RR, 0.34; 95% CI, 0.17-0.69; P-score, 0.715), and sitagliptin (RR. 0.51; 95% CI, 0.37-0.71; P-score, 0.515). ConclusionSGLT-2 inhibitors are associated with the least documented hypoglycemic events and adverse outcomes compared with other oral hypoglycemic drugs. These findings could have considerable public health and clinical implications when extrapolated to the global Muslim population with a similar clinical background. O_FIG O_LINKSMALLFIG WIDTH=193 HEIGHT=200 SRC="FIGDIR/small/22275730v1_ufig1.gif" ALT="Figure 1"> View larger version (103K): org.highwire.dtl.DTLVardef@19a1e6corg.highwire.dtl.DTLVardef@1435cdeorg.highwire.dtl.DTLVardef@1860b0forg.highwire.dtl.DTLVardef@1403efc_HPS_FORMAT_FIGEXP M_FIG C_FIG
Matching journals
The top 9 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Type 1 and type 2 diabetes mellitus: Clinical outcomes due to COVID-19. Protocol of a systematic literature review 96%
- Association of METS-IR Index with Type 2 Diabetes: A Cross-sectional Analysis of National Health and Nutrition Examination Survey Data from 2009 to 2018 94%
- Predictors of glycemic control, quality of life and diabetes self-management of patients with diabetes mellitus at a tertiary hospital in Ghana 94%
Similar papers in this journal
- Time In Range, as measured by continuous glucose monitor, as a predictor of microvascular complications in type 2 diabetes– A systemic review 94%
- The clinical outcomes and effectiveness of mHealth interventions for diabetes and hypertension: a systematic review and meta-analysis 94%
- Comprehensive validation of fasting- and oral glucose tolerance test-based indices of insulin secretion against gold-standard measures 93%
Similar papers in this journal
- Glucagon-like peptide-1 receptor agonists modestly reduced blood pressure among patients with and without diabetes mellitus: A meta-analysis and meta-regression 93%
- A Microbiome-targeting Fiber-enriched Nutritional Formula is Well Tolerated and Improves Quality of Life and Hemoglobin A1c in Type 2 Diabetes: A Double-Blind, Randomized, Placebo-Controlled Trial 93%
- Covid-19 fatality prediction in people with diabetes and prediabetes using a simple score at hospital admission 93%
Similar papers in this journal
- Efficacy and safety of GLP-1 receptor agonists versus SGLT-2 inhibitors in overweight/obese patients with or without diabetes mellitus: a systematic review and network meta-analysis 98%
- Cohort profile: The Nanjing Diabetes Cohort database – a population-based surveillance cohort 94%
- Anti-Diabetic and Antiresorptive Pharmacotherapies for Prevention and Treatment of Type 2 Diabetes-Induced Bone Disease: Protocol for a Two-Part Systematic Review and Network Meta-Analysis 93%
Similar papers in this journal
- Use of evidence-based cardiovascular preventive therapies in type 2 diabetes patients with established or high risk of atherosclerotic cardiovascular disease in China: A retrospective cohort study 94%
- Circulating adipokines in non-obese PCOS patients: a systematic review and meta-analysis 94%
- Association Between Life’s Essential 8 and Atherogenic Index of Plasma in Adults: Insights from NHANES 2007-2018 91%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.